Eli Lilly Expands Access to Experimental Obesity Drug Retatrutide
Eli Lilly has announced that it will allow more patients to apply for special access to retatrutide, an unapproved obesity drug, following requests from doctors. This decision comes after the company granted a single patient access to the drug, prompting inquiries from healthcare providers. Lilly's move marks a shift in its approach to the drug's availability, aligning with FDA guidance for expanded access to investigational treatments. 
